Ubs Asset Management Americas Inc Cassava Sciences Inc Transaction History

Ubs Asset Management Americas Inc

$417 Billion
Q4 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 75,084 shares of SAVA stock, worth $208,733. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,084

Previous 60,894 23.3%

Holding current value

$208,733

Previous $1.79 Million 90.12%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.29 - $32.18 $32,495 - $456,634	14,190 Added 23.3%	75,084 $177,000
Q3 2024 Nov 14, 2024	SELL	$9.57 - $35.08 $125,127 - $458,671	-13,075 Reduced 17.68%	60,894 $1.79 Million
Q2 2024 Aug 13, 2024	BUY	$12.35 - $26.11 $341,959 - $722,959	27,689 Added 59.83%	73,969 $913,000
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $341,155 - $529,910	14,542 Added 45.82%	46,280 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $83,181 - $132,038	2,990 Added 10.4%	31,738 $937,000
Q3 2022 Nov 14, 2022	SELL	$16.33 - $51.06 $61,694 - $192,904	-3,778 Reduced 11.62%	28,748 $1.2 Million
Q2 2022 Aug 12, 2022	BUY	$17.22 - $38.47 $7,180 - $16,041	417 Added 1.3%	32,526 $914,000
Q1 2022 May 16, 2022	BUY	$32.6 - $53.05 $186,700 - $303,817	5,727 Added 21.71%	32,109 $1.19 Million
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $179,915 - $444,822	-4,893 Reduced 15.65%	26,382 $1.15 Million
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $8,399 - $27,195	-201 Reduced 0.64%	31,275 $1.94 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $1.01 Million - $2.82 Million	31,476 New	31,476 $2.69 Million

Others Institutions Holding SAVA

# of Institutions

190

Shares Held

16.4M

Call Options Held

3.49M

Put Options Held

8.08M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $111M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Cassava Sciences Inc Transaction History